New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:05 EDTJAZZJazz Pharmaceuticals agrees to acquire rights to defibrotide in Americas
Jazz Pharmaceuticals announced that the company has signed a definitive agreement with Sigma-Tau Pharmaceuticals under which a subsidiary of Jazz Pharmaceuticals will acquire from Sigma-Tau rights to defibrotide in the United States and all other countries in the Americas. Sigma-Tau holds rights to market defibrotide in the Americas under an agreement with Gentium S.p.A., which was acquired by Jazz earlier this year. As part of the agreement, Sigma-Tau would receive an upfront payment of $75M upon closing of the transaction. Sigma-Tau would be eligible to receive milestone payments of $25M upon the acceptance for filing by the FDA of the first NDA for defibrotide for VOD and up to an additional $150M based on the timing of potential FDA approval of defibrotide for VOD. Jazz expects to fund the transaction with cash on hand and that the transaction will close during the third quarter of 2014, subject to customary closing conditions, including expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
07:48 EDTJAZZJazz Pharmaceuticals price target raised to $177 from $171 at Leerink
Leerink raised its price target for Jazz Pharmaceuticals shares to $177 citing an improved outlook for defibrotide. The firm keeps an Outperform rating on the stock.
July 28, 2014
11:36 EDTJAZZCANbridge Life Sciences and EUSA Pharma form agreement to commercialize Caphosol
CANbridge Life Sciences has entered into an exclusive partnership with EUSA Pharma, a Jazz Pharmaceuticals company, to commercialize CaphosolŪ in China. Under the terms of the agreement, CANbridge obtains exclusive rights to commercialize Caphosol in China, where over 3.5M new cancer cases are diagnosed each year, and there is little in the way of a standard adjunct therapy to treat oral mucositis. Caphosol is a prescription medical device, approved in the United States and European Union, designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx.
July 23, 2014
08:29 EDTJAZZJazz Pharmaceutical initiated with a Buy at Buckingham
Target $215.
08:10 EDTJAZZDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTJAZZJazz Pharmaceuticals initiated with a Buy at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use